Some of these biomarkers, including E2F8 [42], TPX2 [43] and CACNA1D [44], have been independently confirmed as tumourigenic or tumour-suppressive in breast cancer, and can thus point towards novel targets for treatment. This evidence concerns the gene TPX2 and breast carcinoma.